sur Xenetic Biosciences, Inc. (NASDAQ:XBIO)
Xenetic Biosciences Reports Q1 2025 Financial Results
Xenetic Biosciences Inc. disclosed its first-quarter financial results for 2025, emphasizing ongoing collaborations and development initiatives. The company, noted for its immuno-oncology technologies, continues to concentrate on the progression of its DNase I program towards an IND and forthcoming human studies for pancreatic carcinoma treatment. They concluded the quarter with $5.2 million in cash to support future operations.
Collaborations with partners like PeriNess Ltd. were highlighted, advancing DNase's potential for treating osteosarcoma and Ewing sarcoma. Additionally, progress was noted in preclinical studies concerning DNase I combinations with therapies for colorectal cancer. Financially, Q1 revealed a net loss of $0.9 million with a slight revenue increase of 16.1% to $0.6 million, while operational costs decreased due to prior executive departures.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Xenetic Biosciences, Inc.